Helmholtz Gemeinschaft


A high content screening assay for evaluation of biomaterial-mediated cell fusion processes

Item Type:Article
Title:A high content screening assay for evaluation of biomaterial-mediated cell fusion processes
Creators Name:Rijckaert, B. and Neffe, A.T. and Roch, T. and Gebauer, T. and Pierce, B.F. and Görs, J. and Smink, J.J. and Gossen, M. and Lendlein, A. and Leutz, A.
Abstract:Biomaterials are of increasing importance in regenerative medicine and entail delivery systems in somatic cell therapies, matrices for tissue engineering or tissue regeneration. The evaluation of biomaterial induced biological effects remains a key issue in clinical application. Cell-based assays for potential cytotoxic and immunological responses have been developed but are often inadequate to address cell-type specific responses to biomaterials. To quantitatively monitor attachment, survival, proliferation and fusion-controlled differentiation of osteoclasts (bone resorbing cells), a High Content Screening (HCS) assay has been developed based on osteoclast differentiation of the murine monocytic cell line RAW 264.7. This assay was applied to investigate the influence of degradation products of polymers from gelatin and lysine diisocyanate, which display tailorable mechanical properties and have potential as biomaterials. The data show that the degradation products inhibit formation of multinuclear osteoclasts and suggest a potential support of bone regeneration by suppression of bone resorption.
Keywords:Biocompatibility, Biomaterial Degradation, High Content Screening, Osteoclasts
Source:Macromolecular Symposia
Page Range:91-99
Date:December 2014
Official Publication:https://doi.org/10.1002/masy.201400147

Repository Staff Only: item control page

Open Access
MDC Library